In a spectacular reversal of fortunes, ImmuPharma PLC has seen its stock treble after inking a licensing deal with Avion Pharmaceuticals LLC potentially worth almost $100m for Lupuzor, the UK biotech's lupus drug which had been written off by many observers.
ImmuPharma Soars On Avion Lupus Deal
Validates Management Faith In Lupuzor
US speciality drugs group will fund the $25m costs of the UK company's new Phase III trial of Lupuzor, which has been much maligned by analysts.
